Literature DB >> 27614450

Long-term clinical effect of Tangyiping Granules () on patients with impaired glucose tolerance.

Yan-Qin Huang1, Qing-Feng Yang1, Hua Wang1, Yun-Sheng Xu2, Wei Peng1, Yue-Hua Jiang1.   

Abstract

OBJECTIVE: To evaluate the long-term clinical effect of Tangyiping Granules (, TYP) on patients with impaired glucose tolerance (IGT) to achieve normal glucose tolerance (NGT) and hence preventing them from conversion to diabetes mellitus (DM).
METHODS: In total, 127 participants with IGT were randomly assigned to the control (63 cases, 3 lost to follow-up) and treatment groups (64 cases, 4 lost to follow-up) according to the random number table. The control group received lifestyle intervention alone, while the patients in the treatment group took orally 10 g of TYP twice daily in addition to lifestyle intervention for 12 weeks. The rates of patients achieving NGT or experiencing conversion to DM as main outcome measure were observed at 3, 12, and 24 months after TYP treatment. The secondary outcome measures included fasting plasma glucose (FPG), 2-h postprandial plasma glucose (2hPG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS), 2-h insulin (2hINS), homeostatic model assessment of insulin resistance (HOMA-IR), blood lipid and patients' complains of Chinese medicine (CM) symptoms before and after treatment.
RESULTS: A higher proportion of the treatment group achieved NGT compared with the control group after 3-, 12- and 24-month follow-up (75.00% vs. 43.33%, 58.33% vs. 35.00%, 46.67% vs. 26.67%, respectively, P<0.05). The IGT to DM conversion rate of the treatment group was significantly lower than that of the control group at the end of 24-month follow-up (16.67% vs. 31.67%, P<0.05). Before treatment, FPG, 2hPG, HbA1c, FINS, 2hINS, HOMA-IR, triglyceride (TG), total cholesterol, low- and high-density lipoprotein cholesterol levels had no statistical difference between the two groups (P>0.05). After treatment, the 2hPG, HbA1c, HOMA-IR, and TG levels of the treatment group decreased significantly compared with those of the control group (P<0.05). CM symptoms such as exhaustion, irritability, chest tightness and breathless, spontaneous sweating, constipation, and dark thick and greasy tongue were significantly improved in the treatment group as compared with the control group (P<0.05). No severe adverse events occurred.
CONCLUSION: TYP administered at the IGT stage with a disciplined lifestyle delayed IGT developing into type 2 DM.

Entities:  

Keywords:  Chinese medicine; Tangyiping Granules; conversion of impaired glucose tolerance; long-term clinical effect

Mesh:

Substances:

Year:  2016        PMID: 27614450     DOI: 10.1007/s11655-016-2512-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  25 in total

1.  Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids.

Authors:  Paula Trumbo; Sandra Schlicker; Allison A Yates; Mary Poos
Journal:  J Am Diet Assoc       Date:  2002-11

Review 2.  Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Elizabeth Sumamo Schellenberg; Donna M Dryden; Ben Vandermeer; Christine Ha; Christina Korownyk
Journal:  Ann Intern Med       Date:  2013-10-15       Impact factor: 25.391

3.  Antidiabetic mechanism of Coptis chinensis polysaccharide through its antioxidant property involving the JNK pathway.

Authors:  Shuang Jiang; Yahong Wang; Dayong Ren; Jianrui Li; Guangxin Yuan; Liping An; Peige Du; Jie Ma
Journal:  Pharm Biol       Date:  2015-04-10       Impact factor: 3.503

4.  Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.

Authors:  Shinji Ishikawa; Masayuki Shimano; Masato Watarai; Masayoshi Koyasu; Tomohiro Uchikawa; Hideki Ishii; Yasuya Inden; Kenji Takemoto; Toyoaki Murohara
Journal:  Am J Cardiol       Date:  2014-05-16       Impact factor: 2.778

5.  Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early Type 2 diabetes mellitus.

Authors:  Yongcai Zhao; Xinsheng Li; Shiling Tang
Journal:  Diabetes Res Clin Pract       Date:  2015-05-15       Impact factor: 5.602

6.  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.

Authors:  X R Pan; G W Li; Y H Hu; J X Wang; W Y Yang; Z X An; Z X Hu; J Lin; J Z Xiao; H B Cao; P A Liu; X G Jiang; Y Y Jiang; J P Wang; H Zheng; H Zhang; P H Bennett; B V Howard
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

Review 7.  Traditional chinese medicine in treatment of metabolic syndrome.

Authors:  Jun Yin; Hanjie Zhang; Jianping Ye
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-06       Impact factor: 2.895

8.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

Review 9.  Prevention of type 2 diabetes: data from recent trials.

Authors:  A M Kanaya; K M Narayan
Journal:  Prim Care       Date:  2003-09       Impact factor: 2.907

10.  Fasting plasma glucose as initial screening for diabetes and prediabetes in irish adults: The Diabetes Mellitus and Vascular health initiative (DMVhi).

Authors:  Margaret Sinnott; Brendan T Kinsley; Abaigeal D Jackson; Cathal Walsh; Tony O'Grady; John J Nolan; Peter Gaffney; Gerard Boran; Cecily Kelleher; Bernadette Carr
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

View more
  4 in total

1.  Verification of the Efficacy and Safety of Qi-Replenishing Chinese Medicine in Treating Prediabetes: A Meta-Analysis and Literature Review.

Authors:  Shujie Xia; Bizhen Gao; Shujiao Chen; Xuejuan Lin; Ping Zhang; Yujuan Chai; Candong Li; Tetsuya Asakawa
Journal:  Evid Based Complement Alternat Med       Date:  2020-11-10       Impact factor: 2.629

2.  Efficiency and Safety of Chinese Herbal Medicine in the Treatment of Prediabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Yanan Song; Haiyan Wang; Lingling Qin; Mei Li; Saiyue Gao; Lili Wu; Tonghua Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-10-14       Impact factor: 2.629

Review 3.  Efficacy of Chinese herbal medicine for stroke modifiable risk factors: a systematic review.

Authors:  Wenbo Peng; Romy Lauche; Caleb Ferguson; Jane Frawley; Jon Adams; David Sibbritt
Journal:  Chin Med       Date:  2017-09-05       Impact factor: 5.455

4.  Identifying potential therapeutic targets of Tang-Yi-Ping for the treatment of impaired glucose tolerance: a tandem mass tag-labeled quantitative proteomic analysis.

Authors:  Jie Li; Shuai Bu; Honglei Zhou; Siling Bi; Yunsheng Xu
Journal:  Ann Transl Med       Date:  2021-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.